DOSSIER · 13F-HR · Q2 2026

First Light Asset Management, LLC

$1.6B in tracked AUM across 31 positions as of Q2 2026.

FL
CIK 0001600004 · last filed Jun 30, 2026
Total AUM
$1.6B
as of Q2 2026
Holdings
31
positions
Whale Score
75
75
strong
Activity
no data
changes this Q
AI Analysis · Q2 2026

Based on the SEC 13F filing data for First Light Asset Management, LLC as of September 30, 2025, here is a comprehensive analysis of the portfolio's composition, activity, and strategic orientation.

1. Portfolio Overview

First Light Asset Management manages a highly concentrated portfolio totaling approximately $598.65 million across 21 holdings. The firm experienced a significant reduction in assets under management (AUM) this quarter, with the portfolio value declining by **22.4%...

This decrease in value is attributable to two factors: a substantial reduction in the number of holdings (from a higher implied count to 21) and the inherent volatility associated with the fund's specific focus. The portfolio is characterized by high conviction, with the top 10 positions accounting for approximately 79% of the total portfolio value. The fund appears to follow a specialized strategy, likely targeting small-to-mid-cap growth companies, with a heavy emphasis on the healthcare and biotechnology sectors. The "Unknown" sector classification, representing roughly 40% of the portfolio, likely consists of biotechnology or specialized technology firms that may not fit neatly into standard sector categorizations or are American Depositary Receipts (ADRs).

2. Key Holdings

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
NEO
NEOGENOMICS INC
$179M12.3M10.9%
02
SIBN
SI-BONE INC
$133M8.1M8.1%
03
AXGN
AXOGEN INC
$127M2.7M7.7%
04
APGE
APOGEE THERAPEUTICS INC
$123M930K7.5%
05
PVLA
PALVELLA THERAPEUTICS INC
$118M772K7.2%
06
TWST
TWIST BIOSCIENCE CORPORATION
$75M728K4.6%
07
ELVN
ENLIVEN THERAPEUTICS INC
$69M1.4M4.2%
08
GH
GUARDANT HEALTH
$66M442K4.0%
09
MASS
908 DEVICES INC
$55M6.3M3.3%
10
AMLX
AMYLYX PHARMACEUTICALS INC
$54M3.0M3.3%

Filing history

2026Q2Jun 30
$1.6B 47.4%
31 positionsView →
2026Q1Mar 31
$1.1B 14.7%
35 positionsView →
2025Q4Dec 31
$1.3B 118.5%
33 positionsView →
2025Q3Sep 30
$599M 22.4%
21 positionsView →
2025Q2Jun 30
$771M 11.9%
38 positionsLocked
2025Q1Mar 31
$876M 16.2%
37 positionsLocked
2024Q4Dec 31
$1.0B 13.0%
36 positionsLocked
2024Q3Sep 30
$1.2B 5.4%
38 positionsLocked
2024Q2Jun 30
$1.1B 12.7%
44 positionsLocked
2024Q1Mar 31
$1.3B 5.1%
50 positionsLocked
2023Q4Dec 31
$1.2B 18.1%
75 positionsLocked
2023Q3Sep 30
$1.1B 17.5%
75 positionsLocked
Showing 12 of 48